問卷

TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Geriatrics

Division of Thoracic Medicine

Division of Infectious Disease

Division of General Internal Medicine

Division of Thoracic Medicine

更新時間:2024-05-13

許超群Sheu, Chau-Chyun
  • Principal Investigator
  • Clinical Trial Experience (year) 8 years

篩選

List

100Cases

2022-11-01 - 2025-01-07

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting8Sites

2024-07-01 - 2027-11-28

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2022-11-01 - 2025-04-14

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting8Sites

2023-10-02 - 2028-01-05

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-10-16 - 2027-09-09

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-01-01 - 2023-01-24

Phase III

-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Terminated7Sites

2022-10-01 - 2026-01-16

Phase III

An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive Candidiasis
  • Condition/Disease

    Adult patients with candidemia and/or invasive candidiasis

  • Test Drug

    Fosmanogepix CANCIDAS Fosmanogepix Caspofungin Fluconazole

Participate Sites
2Sites

Recruiting2Sites

2021-05-01 - 2023-10-30

Phase II

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis
  • Condition/Disease

    Pulmonary Fibrosis

  • Test Drug

    BMS-986278

Participate Sites
3Sites

Recruiting3Sites

2020-01-03 - 2021-03-08

Phase III

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Efficacy and Safety of AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus
  • Condition/Disease

    AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus

  • Test Drug

    AR-301 Tosatoxumab

Participate Sites
10Sites

Not yet recruiting9Sites

Recruiting1Sites